Metastatic melanoma responds to first-line interleukin-21

August 23, 2012
Metastatic melanoma responds to first-line interleukin-21
In the first-line treatment of metastatic melanoma, interleukin-21 shows an overall response rate of 22.5 percent and warrants further study, according to research published online Aug. 20 in the Journal of Clinical Oncology.

(HealthDay)—In the first-line treatment of metastatic melanoma, interleukin-21 (IL-21) shows an overall response rate (ORR) of 22.5 percent and warrants further study, according to research published online Aug. 20 in the Journal of Clinical Oncology.

Teresa M. Petrella, M.D., of the Sunnybrook Odette Cancer Centre in Toronto, and colleagues conducted a phase 2, multicenter study to evaluate the efficacy and safety of IL-21 in patients with . Two of the groups received either 30 µg/kg per day (30 patients) or 50 µg/kg per day (three patients) by intravenous bolus for five days of each week during weeks one, three, and five of an eight-week cycle. A third group received 50 µg/kg per day (seven patients) for five days of each week during weeks one and three of a six-week cycle.

The researchers found that treatment-related adverse events included fatigue, rash, diarrhea, nausea, and myalgia. The ORR was 22.5 percent, with nine partial responses and 16 with stable disease. Median duration of response for all responders was 5.3 months. Response was not dependent on either BRAF mutation status or IL-21 . Overall, median progression-free survival was 4.3 months and median overall survival was 12.4 months.

"Promising antitumor activity was observed at both doses and schedules used in this trial, although the numbers treated are too small for definitive comparisons to be made," the authors write. "Responses were seen at all disease sites, including skin, , lung, liver, and other visceral organs."

Two study authors disclosed receiving research funding from ZymoGenetics.

Explore further: New drug, Vemurafenib, doubles survival of metastatic melanoma patients

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Tivozanib exhibits antitumor activity in renal cancer

April 10, 2012

(HealthDay) -- The potent, selective vascular endothelial growth factor receptor-1, -2, and -3 inhibitor, tivozanib, demonstrates antitumor activity and is well tolerated in patients with advanced/metastatic renal cell carcinoma ...

Chemo combination promising for multiple myeloma

May 2, 2012

(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according ...

Regorafenib active in metastatic GI stromal tumors

May 23, 2012

(HealthDay) -- Regorafenib, an inhibitor of multiple cancer-associated kinases, is active in patients with metastatic gastrointestinal stromal tumors (GIST) who have failed to respond to imatinib and sunitinib, according ...

ASCO: Trametinib improves survival in metastatic melanoma

June 5, 2012

(HealthDay) -- For patients with metastatic melanoma with activating mutations in serine-threonine protein kinase B-RAF (BRAF), treatment with the oral selective MEK inhibitor trametinib is associated with improved progression-free ...

Recommended for you

The growing menace of HPV‑related throat and mouth cancers

February 2, 2016

There's a new cancer epidemic on the rise. It's an aggressive throat and mouth cancer caused by the human papillomavirus (HPV)—the same sexually transmitted virus that leads to cervical cancer—but it's affecting mostly ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.